August 6, 2015
VBL Therapeutics to Report Second Quarter 2015 Financial Results on August 13, 2015
TEL AVIV, Israel, Aug. 6, 2015 (GLOBE NEWSWIRE) — VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2015 at 8:30 a.m. ET to report second quarter 2015 financial results.
To participate in the conference call, please dial 1-646-254-3364 (domestic) or +972-3-763-0147 (international) and refer to conference ID 7639030. The live webcast of the call can be accessed in the Investors section of the Company’s website at www.vblrx.com. An archived webcast will be available on the Company’s website beginning approximately two hours after the event.
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 clinical trial of VB-111 in rGBM shortly, under a special protocol assessment granted by the FDA.
Forward Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. In particular, results from our proposed pivotal Phase 3 clinical trial of VB-111 in rGBM may not support approval of VB-111 for marketing in the United States, notwithstanding the positive results seen in our current clinical trial. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACT: Hannah Deresiewicz
Stern Investor Relations, Inc.
(212) 362-1200, firstname.lastname@example.org